Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of HS627 vs PERJETA in Healthy Male Subjects
NCT05323981Phase 1Completed
- Sponsor
- BioRay Pharmaceutical
- Start
- Apr 2022
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of hs627 in HER2-positive breast cancer (3 arms), sponsored by BioRay Pharmaceutical. Primary endpoint: Area Under the Serum Concentration-Time Curve From Time Zero to Infinity at 85 Days. Started Apr 2022; status: completed.
02
Drugs
hs627
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT05323981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05323981.